Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Zevra Therapeutics (ZVRA) Return on Capital Employed (2016 - 2025)

Historic Return on Capital Employed for Zevra Therapeutics (ZVRA) over the last 10 years, with Q3 2025 value amounting to 0.37%.

  • Zevra Therapeutics' Return on Capital Employed rose 2800.0% to 0.37% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.37%, marking a year-over-year increase of 2800.0%. This contributed to the annual value of 0.62% for FY2024, which is 900.0% up from last year.
  • As of Q3 2025, Zevra Therapeutics' Return on Capital Employed stood at 0.37%, which was up 2800.0% from 0.64% recorded in Q2 2025.
  • Over the past 5 years, Zevra Therapeutics' Return on Capital Employed peaked at 0.11% during Q1 2021, and registered a low of 0.65% during Q3 2024.
  • For the 5-year period, Zevra Therapeutics' Return on Capital Employed averaged around 0.34%, with its median value being 0.4% (2022).
  • Its Return on Capital Employed has fluctuated over the past 5 years, first soared by 15900bps in 2021, then tumbled by -5600bps in 2023.
  • Quarter analysis of 5 years shows Zevra Therapeutics' Return on Capital Employed stood at 0.06% in 2021, then plummeted by -783bps to 0.4% in 2022, then crashed by -50bps to 0.61% in 2023, then increased by 5bps to 0.58% in 2024, then soared by 36bps to 0.37% in 2025.
  • Its Return on Capital Employed stands at 0.37% for Q3 2025, versus 0.64% for Q2 2025 and 0.48% for Q1 2025.